Skip to content

A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05806996
Enrollment
120
Registered
2023-04-10
Start date
2023-06-30
Completion date
2026-06-30
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Spasms

Brief summary

This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.

Interventions

DRUGMagnesium

Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour

DRUGPlacebo

Equivalent volume of normal saline

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Be undergoing a bladder invasive procedure with or without planned urinary catheter on Mayo Clinic Gonda 7 Outpatient Procedure Center.

Exclusion criteria

* Are unable to grant informed consent or comply with study procedure. * Allergy or known sensitivity to magnesium or Renacidin. * Expected or high risk of bladder extravasation. * Ongoing atrial fibrillation prior to surgery. * Are undergoing emergency surgery. * Are pregnant. * Known hypermagnesemia. * Patients with neuromuscular weakness (e.g., Myasthenia gravis) due to magnesium's muscle weakening effect. * Patients with myocardial compromise or cardiac conduction defects because of magnesium's anti-inotropic effects. * Patients with renal insufficiency, glomerular filtration rate less than 30, since Magnesium is eliminated by the kidneys resulting in exaggerated rise in serum magnesium. * Patients with concomitant use of a calcium channel blocker since magnesium sulfate could act synergistically to suppress muscular contractility.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of bladder spasmPost-operative, approximately 1 hourNumber of subjects to experience bladder spasms

Secondary

MeasureTime frameDescription
Incidence of bladder spasm above moderate gradePost-operative, approximately 4 hoursNumber of subjects to experience bladder spasms above moderate grade
Treatment for bladder spasmsPost-operative, approximately 4 hoursNumber of subjects requiring treatment for bladder spasms
Patient satisfactionPost-operative, approximately 4 hoursAssessed using a seven-point Likert scale where 1=strongly dissatisfied, 2=moderately dissatisfied, 3=slightly dissatisfied, 4=neutral, 5=slightly satisfied, 6=moderately satisfied, 7=extremely satisfied

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGregory Nuttall, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026